1. OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2. (15th June 2017) Authors: McInnes, IB; Mease, PJ; Ritchlin, C; Rahman, P; Gottlieb, A; Kirkham, B; Kajekar, R; Delicha, EM; Pricop, L; Mpofu, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗